ITCI
Intra-cellular Therapies, Inc.
$85.45
Earnings Summary
Revenue | $175.16Mn |
Net Profits | $-26.32Mn |
Net Profit Margins | -15.03% |
Highlights
Intra-cellular Therapies, Inc.’s revenue jumped 39.23% since last year same period to $175.16Mn in the Q3 2024. On a quarterly growth basis, Intra-cellular Therapies, Inc. has generated 8.53% jump in its revenue since last 3-months.
Intra-cellular Therapies, Inc.’s net profit fell -8.52% since last year same period to $-26.32Mn in the Q3 2024. On a quarterly growth basis, Intra-cellular Therapies, Inc. has generated -62.29% fall in its net profits since last 3-months.
Intra-cellular Therapies, Inc.’s net profit margin jumped 22.06% since last year same period to -15.03% in the Q3 2024. On a quarterly growth basis, Intra-cellular Therapies, Inc. has generated -49.53% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Intra-cellular Therapies, Inc. post its latest quarter earnings
EPS Estimate Current Year | -0.32 |
Highlights
Intra-cellular Therapies, Inc.’s earning per share (EPS) estimates for the current year stand at -0.32.
Key Ratios
Key ratios of the Intra-cellular Therapies, Inc. post its Q3 2024 earnings
Earning Per Share (EPS) | -0.25 |
Highlights
Intra-cellular Therapies, Inc.’s earning per share (EPS) jumped 0% since last year same period to -0.25 in the Q3 2024. This indicates that the Intra-cellular Therapies, Inc. has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-07 | -0.32 | -0.16 | 50% |
2024-10-30 | -0.2 | -0.25 | -25% |
2024-08-07 | -0.19 | -0.16 | 15.79% |
₹0 US Stocks a/c Opening Fee